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Crystal Structure of Protein C Inhibitor
Provides Insights into Hormone Binding
and Heparin Activation
( sheet A). The ester bond between the active site serine
of the protease and the reactive center carbonyl carbon
of the serpin is stabilized by the destruction of the active
site architecture, as the result of a pulling stress placed
on the protease in the final complex (for review see [13]).
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Cambridge Institute for Medical Research PCI is thus a heparin-activated serpin, but, unlike
Wellcome Trust/MRC Building other heparin binding serpins (plasminogen activator I,
Hills Road antithrombin [AT], heparin cofactor II [HCII], and prote-
Cambridge CB2 2XY ase nexin I), the heparin binding region of PCI does not
United Kingdom include helix D [14]. Several mutagenesis studies have
2 Department of Clinical Chemistry instead suggested that heparin binding involves basic
Lund University residues on helix H [15]. Heparin and other polysul-
University Hospital phated glycosaminoglycans (GAGs) bind PCI in a non-
S-20502 Malmo¨ specific manner and accelerate the inhibition of prote-
Sweden ases, which also bind GAGs through a template effect,
also known as the bridging mechanism [16]. The pro-
posed GAG bridging mechanism for the interaction of
PCI and APC is similar to that for AT and thrombinSummary
[17], where the inhibitor and the protease each bind to
separate sites on the same GAG chain for the formationProtein C inhibitor (PCI) is a member of the serpin
of the productive Michaelis complex.family that has many biological functions. In blood it
PCI is located in many tissues and is found at a partic-acts as a procoagulant, and, in the seminal vesicles,
ularly high concentration in seminal plasma, where itit is required for spermatogenesis. The activity of PCI
inhibits the prostate-specific antigen acrosin and tissueis affected by heparin binding in a manner unique
kallikrein [18–20]. In mice, PCI is only synthesized in theamong the heparin binding serpins, and, in addition,
genital tract, where it is required for spermatogenesisPCI binds hydrophobic hormones with apparent speci-
and male fertility [21]. Consistent with its role in develop-ficity for retinoids. Here we present the 2.4 A˚ crystallo-
graphic structure of reactive center loop (RCL) cleaved ment, PCI is capable of binding several hydrophobic
PCI. A striking feature of the structure is a two-turn hormones with an apparent specificity for retinoids [22].
N-terminal shortening of helix A, which creates a large Two other members of the serpin family are known to
hydrophobic pocket that docking studies indicate to function as hormone binding proteins, corticosteroid
be the retinoid binding site. On the basis of surface binding protein (CBG) and thyroxine binding globulin
electrostatic properties, a novel mechanism for hepa- (TBG). Both CBG and TBG are noninhibitory serpins that
rin activation is proposed. have maintained the ability to undergo the conforma-
tional rearrangement associated with protease inhibition
[23]. The affinity of CBG for cortisol is reduced by 10-Introduction
fold after cleavage of the RCL, but, for TBG and PCI,
hormone binding is not significantly affected by cleav-Protein C inhibitor (PCI) is a serpin of many functions
age [23–25]. This has fostered speculation that the hor-(see [1] for review). It derives its name from the ability
mone binding sites for these serpins may be different.to inhibit the anticoagulant activated protein C (APC) in
Molecular modeling and docking studies have been car-the circulation, but it can also inhibit thrombin, thrombin
ried out to determine the mode of hormone interactionbound to thrombomodulin (TM), urokinase, factor Xa,
factor XIa, tissue plasminogen activator, and tissue and with CBG and TBG and suggest a binding site located
plasma kallikrein [2–8]. All of these reactions are acceler- in the  barrel formed by sheets B and C [26]. More
ated by the cofactor heparin or heparan sulfate, with the recent modeling studies, based on the structure of
single exception of tissue kallikrein, which is resistant to cleaved 1-antichymotrypsin, suggest that cortisol binds
inhibition by PCI in the presence of heparin [1, 8–11]. CBG in a pocket between sheet B and helix H [27].
The mechanism by which serpins, such as PCI, inhibit Here we present the structure of cleaved PCI to 2.4 A˚
serine proteases has recently been revealed by the crys- resolution. Its overall fold is similar to other RCL cleaved
tallographic structure of the final serpin-protease com- inhibitory serpins, with the single exception of a two-
plex [12]. The mechanism involves the formation of a turn N-terminal shortening of helix A. This surprising
productive docking (Michaelis) complex and entry into structural feature creates a large hydrophobic pocket
the proteolytic cycle. After the formation of the acyl- that docking studies indicate to be the binding site for
enzyme intermediate, the protease is translocated to retinoic acid. An extended heparin binding site based
the opposite pole of the serpin through the rapid incor- on surface electrostatic properties is proposed, which
poration of the RCL of the serpin into its main  sheet helps explain the repulsive interaction of PCI with APC
and thrombin in the absence of GAG and suggests a
novel mechanism of GAG activation.*Correspondence: jah52@cam.ac.uk
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Figure 1. Crystallographic Structure of
Cleaved PCI
The asymmetric unit (A) contains four mole-
cules of PCI, which were essentially identical.
The RCL of each (yellow) was found inserted
as strand 4 of  sheet A (red). The monomer
described in the text and in subsequent fig-
ures is gray; helix A, green; the proposed hep-
arin binding helix H, cyan. A stereo represen-
tation of cleaved PCI (colored as in [A])
superimposed on cleaved 1-antitrypsin (light
blue, transparent) (B) reveals the striking two-
turn shortening of helix A, the resulting shift
in position of helix H, and the three-residue
truncation of the  turn between strands 4
and 5B (magenta).
Results with C rmsd’s of 0.84, 0.77, and 0.88 A˚ for AB, CD,
and EF, respectively, when superimposed on the best-
defined monomer (denoted GH in the deposition 1LQ8)Overall Structure
The four molecules of cleaved PCI that comprise the for the 356 equivalent atoms. It was not surprising to find
 sheet A with six strands, the fourth being composed ofasymmetric unit (Figure 1A; Table 1) are nearly identical,
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Table 1. Data Processing, Refinement, and Model (1LQ8)
Crystal
Space group P21
Cell dimensions (A˚) a  55.20, b  244.03, c  66.40
  91.98
Solvent content (%) 37
Data Processing Statistics
Wavelength (A˚) 1.0332 (APS Argonne, Station19-ID)
Resolution (A˚) 45.6–2.4
Total reflections 68,208
Unique reflections 55,034
I/(I) 6.9
I/(I) 19.2
Completeness (%) 81.7
Rmerge 0.148
Model
Number of protein/water atoms 11,547/99
Average B factor (A˚2) 64.8
Refinement Statistics
Reflections in working/free set 53,415/1,619
R factor/Rfree (%) 22.2/27.9
Rmsd of bonds (A˚)/angles () from ideality 0.008/1.5
Ramachandran plot, residues in
Most-favored region (%) 81.9
Additionally allowed region (%) 15.9
Generously allowed region (%) 1.3
Disallowed region (%) 0.9
the RCL, as the inhibitory mechanism is dependent on the surface of cleaved PCI, 15 were in the helix A gap.
The best three “hits” are shown in Figure 3 and differthis thermodynamically driven conformational change.
Thus, cleaved PCI is nearly identical to the cleaved form mainly in the position of the carboxyl group. Figure 3A
is a stereo representation of ribbon diagrams of cleavedof 1-antitrypsin in complex with a protease, with a C
rmsd of 1.90 A˚ for the 329 equivalent atoms. The largest PCI, with 1-antitrypsin superimposed as in Figure 1B
and retinoic acid bound in the three best energy modes.deviation between the structures of cleaved PCI and 1-
antitrypsin is at the N terminus of helix A and in the It is clear from the figure how the binding site is created
by the shortening of helix A and how an A helix of normalposition of helix H, as illustrated in Figure 1B. Helix
A is shorter by two turns in all four molecules in the length would preclude binding by filling the hydrophobic
pocket. The hydrophobic core of retinoic acid fits nicelyasymmetric unit, and electron density in this region (Fig-
ure 2A) confirms this unusual structural feature. It is into the hydrophobic pocket, as illustrated in Figure 3B.
The position of the acidic group varies, with none of theunlikely that helix A is shortened in response to cleavage
and insertion of the RCL into  sheet A, since the struc- best hits participating in any favorable ionic interactions.
While the third-best hit (orange) places the anionic car-tures of other serpins in their native and cleaved forms
show little or no difference in helix A length. Helix H boxyl group in a hydrophobic channel, the first- and
second-best hits (white and yellow) are oriented towardappears to shift position because of the truncation of
helix A, since its position in PCI is very similar to that basic residues on the loop preceding helix A. Thus,
Arg26 and Arg27 could shift slightly to interact with thefound in CrmA, which also has a two-turn-shorter helix
A [28, 29]. The short A helix and the shift in position of acidic groups of the first- and second-best orientations.
Although the hydrophobic groove along helix D is anhelix H creates a large hydrophobic cavity in cleaved
PCI (Figure 2B). attractive site for positioning a linear hydrophobic mole-
cule, such as retinoic acid, none of the top 20 hits were
in this region. The binding stoichiometry has been dem-Retinoic Acid Binding
onstrated to be one to one [22], consistent with theThe hydrophobic pocket created by the N-terminal
clustering of hits in the helix A gap.shortening of helix A provides an attractive potential site
for retinoic acid binding. The “helix A gap” is evident in
the stereo view (Figure 2B) and extends from the N Heparin Binding Site
Generally, heparin binding sites in proteins are identifiedterminus of helix A along helix D. This gap is extended
toward the C terminus of helix D because of the trunca- by analysis of linear sequences. The most common lin-
ear motifs are XBBXBX and XBBBXXBX, where B is ation of three residues in the loop between strands 4 and
5B (Figures 1B and 3A). The helix A gap was identified basic residue and X is uncharged and commonly hy-
drophobic [30]. For this reason, most of the focus onas the retinoic acid binding site with the program Dock-
Vision. Of the 20 best energy binding modes found on the heparin binding site of PCI has centered on the so-
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Figure 2. PCI Has a Shortened Helix A, Resulting in a Large Hydrophobic Pocket
Electron density of the N terminus of PCI (Arg26––Phe31) (A) demonstrates, unequivocally, the shortened length of the helix A. A stereo
representation of the surface of cleaved PCI (B) in the same orientation as in Figure 1B, demonstrates the resulting large hydrophobic gap
(green for hydrophobic).
called A helix [31], composed of the very N-terminal 2B, R234 on strand 2B, and R362 on strand 1C. This
renders the heparin binding region more diffuse thanregion 5HRHHPREMKKR15, and the H helix region,
composed of 266KTLRKWLKMFKKR278. Both regions previously anticipated, as it spans over several second-
ary-structural elements.have been shown to affect heparin binding affinity, but
only helix H mutations have altered rates of inhibition
in the presence of heparin. The structure of cleaved Discussion
PCI allows the investigation of the surface electrostatic
properties of the molecule and suggests that helix H is The structure of cleaved PCI presented here confirms its
structural and mechanistic similarity to other inhibitoryonly a part of a nonlinear heparin binding region (Figures
4A and 4B). Helix H includes residues 265–275 and en- members of the serpin family. Its structure is nearly
identical to that of the prototypical serpin 1-antitrypsin,compasses the previously proposed heparin binding
residues K266, R269, K270, and K273. Other residues which, in its cleaved form, was the first serpin structure
solved [32] and is the only serpin that has been crystal-contributing to the positive electrostatic potential near
the top of cleaved PCI are K276, K277, and R278 on lized in its final complex with a protease [12]. Thus, it
is possible to make comparisons with other serpins, forstrand 2C, R229 in the  turn between strands 1 and
Crystal Structure of Cleaved PCI
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Figure 3. Close-up of the Helix A Gap with the Top Three Retinoic Acid Docking Results
The energetic difference between the top three docking results for retinoic acid was small; white, best; yellow, second best; orange, third
best (ball and stick or rods). The shortening of helix A provides space for the binding of retinoic acid, as demonstrated by the stereo
representation of the ribbon diagram of cleaved PCI superimposed on cleaved 1-antitrypsin (A) (coloring and orientation are the same as in
Figure 1B). The best hits clustered in the helix A gap (B), with the hydrophobic end of retinoic acid buried in the hydrophobic pocket formed
between helices A and D.
which details of the inhibitory mechanism have been The nature of the ternary complex between heparin, AT,
and thrombin is not known, but it requires at least 15revealed by solution studies and protein crystallogra-
phy. Typically, the magnitude of the second-order rate saccharide units for heparin [36] and is not expected to
involve significant interactions between AT and throm-constant of protease inhibition is determined by the sta-
bility of the Michaelis complex, with the rate of acylation bin outside the RCL. HCII inhibition of thrombin more
closely resembles the AT-factor Xa interaction, with thebeing limiting at high concentrations [33]. This provides
an opportunity for regulation that is exploited by several heparin acceleration dependent on extensive exosite
interactions.serpins, most notably, AT and HCII. AT binds heparin
in a well-defined manner [34] and adopts an activated Only two serpins/protease Michaelis complexes have
been solved by X-ray crystallography, the Manducaconformation, which docks with greater affinity to factor
Xa [35], but the nature of the docked complex is un- Sexta serpin 1K with trypsin [37] and HCII with thrombin
[38]. These structures differ markedly in the extent ofknown. Heparin accelerates thrombin inhibition by AT
through a mechanism that is commonly referred to as intermolecular interactions. Serpin 1K and trypsin only
interact via the RCL of the serpin and the active sitethe “bridging mechanism,” which involves AT in a fixed
position, because of its binding to a high-affinity site, cleft of the protease, with each molecule rotating inde-
pendently, as observed with 1-antitrypsin and trypsinand thrombin translating along the heparin chain, be-
cause of its lack of specificity, until it encounters AT. by NMR [39]. The structure of the HCII-thrombin Michae-
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Figure 4. Proposed Nonlinear Heparin Binding Site and Corresponding Sites of Interaction for Target Proteases
The charge contour of cleaved PCI reveals one major electropositive patch on the surface of the molecule adjacent to the RCL of the native
form (A) (the top of the molecule in the classic orientation; blue, positive potential; red, negative potential). Although this patch involves helix
H (cyan), it is not limited to it, with residues from several secondary-structural elements contributing (B) (same orientation as in [A]). In the
Michaelis complex, the surface of PCI that binds heparin is in close proximity to the heparin binding region of APC (yellow oval).
(C) Similarly for thrombin, anion binding exosite I would interact with the heparin binding site of PCI.
(D) Heparin binding to PCI abolishes the inhibition of tissue kallikrein (E), consistent with the heparin binding of PCI reversing the surface
charge of PCI from basic to acidic on the surface that interacts with acidic tissue kallikrein.
lis complex revealed a large interaction interface involv- tion-deficient variant, which inhibits thrombin and
plasma kallikrein approximately five times more rapidlying the docking of thrombin on the surface of  sheet
C of HCII. The Michaelis complex between HCII and than does fully glycosylated wild-type, both in the ab-
sence and presence of heparin. In addition, the heparinthrombin involves both molecules binding to the acidic
N-terminal tail of HCII, which is repositioned in response binding region of PCI corresponds to the surface of HCII
that interacts with the acidic tail and thrombin in theto heparin binding. The electrostatics at the interaction
interface are not complementary in the absence of the Michaelis complex. Thus, models of the Michaelis com-
plexes between PCI and APC, thrombin, and tissue kalli-repositioned acidic tail because of the unfavorable ap-
position of electropositive surfaces (see the Supplemen- krein were created on the basis of the HCII-thrombin
structure. The models suggest that, in order to form atary Material available with this article online and Fig-
ure 4D). Michaelis complex, it is necessary to bring the positively
charged surface of PCI into close proximity to positivelyOne of the unique features of PCI is the location of the
heparin binding site. Support for the extended, nonlinear charged surfaces on APC and thrombin (Figures 4C and
4D). The electropositive surface of PCI corresponds toheparin binding site proposed here is provided by stud-
ies on the properties of PCI glycosylation variants [40]. the heparin binding site, as outlined above (Figure 4A).
Similarly, the electropositive surface in APC, shown inTwo glycosylation sites are near the proposed heparin
binding region, N230 and N243. N230 is in the middle Figure 4C, corresponds to its heparin binding site, as
identified through mutagenic studies [41–43]. Heparinof the basic cleft, adjacent to R229 (Figures 4A and 4B),
and N243 is on the other side of, and in close proximity binding variants of APC, where positively charged resi-
dues on the 37 and 60 loops are replaced with neutralto, helix H. Preventing glycosylation at N230 significantly
increased the affinity of PCI for heparin, whereas no or negatively charged residues, are inhibited by PCI at
significantly higher basal rates than the wild-type. Theeffect was observed for N243. The prediction that the
heparin binding site of PCI corresponds to the protease model of the PCI-APC complex reveals several energeti-
cally unfavorable interactions, including R229 and R234interaction site is also supported by the N230 glycosyla-
Crystal Structure of Cleaved PCI
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with K62 of APC, R367 with K37 of APC, and R362 with hits (among known serpins) were PCI (from other spe-
cies), TBG, 1-antitrypsin, and CBG. Of these, three areK39 of APC. Thus, the residues involved in the potential
interface between PCI and APC are the same as those hormone binding serpins (PCI, TBG, and CBG) and three
are on the same serpin gene cluster on chromosomeidentified as the heparin binding residues. An alternative
to the bridging mechanism, a “cooccupation” mecha- 14q32.1 (PCI, 1-antitrypsin, and CBG), adding strength
to the idea of a structural conservation of the helix Anism, can now be proposed where PCI and APC initially
bind to different sites on heparin and then each migrates gap among the hydrophobic hormone binding serpins.
In addition to sequence similarity and chromosomal lo-to form and encounter complex through the cooccupa-
tion of the same site on heparin (Figure 5). The Michaelis calization, evidence for the critical role of the region
between helices A and D is provided by natural andcomplex would resemble that of HCII and thrombin, with
the acidic tail being replaced with heparin in the PCI- engineered variants of CBG. The most critical residue for
corticosteroid binding by CBG is W371, which protrudesAPC complex. This mechanism is consistent with the
nonabsolute nature of heparin stimulation on heparin into the helix A gap from the turn between strands 4
and 5B (in the model of CBG built on cleaved PCI). Thechain length. Small heparin chains of approximately
seven saccharide units are sufficient for significant ac- conservative substitution of W371F completely abol-
ishes detectable binding of corticosteroid by CBG [48].celeration in rate of APC inhibition by PCI [44], but longer
chains improve the level of acceleration. The apparent This tryptophan helps form the hydrophobic helix A gap
in the model of CBG. Other mutations that affect thedependence on heparin chain length would thus be due
to an improved likelihood of the proteins encountering affinity of CBG for steroid hormones are D367N [49],
which is located on the same loop as W371, and L93Dlonger heparin chains and not to a minimum length re-
quirement for bridging, as demonstrated for AT with [50], which is on helix D, with its side chain underlying
W371 and contributing to the hydrophobic nature ofthrombin or factor Xa [45] and for HCII with thrombin [46].
The mechanism of cooccupation outlined above could the helix A gap. Current proposals for steroid hormone
binding sites of CBG are insufficient to account for thealso work for the heparin acceleration of thrombin inhibi-
tion by PCI, although with some differences. Thrombin effect of these mutations. Another enigmatic observa-
tion is the dependence of the ability of CBG to binddocked on PCI would interact via anion binding exosite
I and, thus, experience charge repulsion in the absence steroid hormones on the protonation state or the chemi-
cal modification of a single unidentified arginine residueof heparin (Figure 4D). Thrombin binds heparin via anion
binding exosite II but is also capable of interacting with [51]. Similarly, a significant protection from chemical
modification of a single arginine is afforded by cortisolheparin via exosite I [47]. It is thus possible that thrombin
in complex with PCI interacts with heparin using both binding to CBG [51]. In the helix A gap of the model of
CBG, there is a single arginine residue (R260), the sideexosites, initially via exosite II and subsequently with
exosite I, after encountering PCI on the same heparin chain of which extends into the gap and is very close
to the critical W371. Thus, the existing evidence fromchain. If this hypothesis of cooccupation is correct, it
must also explain the abolition of tissue kallikrein inhibi- sequence, biochemical, and mutagenic analyses sup-
ports the conservation of a hormone binding site, cre-tion by PCI in the presence of heparin. Figure 4E shows
that the predicted interaction interface of tissue kalli- ated by the N-terminal foreshortening of helix A, among
the hormone binding serpins.krein is overwhelmingly negatively charged. The effect
of heparin binding to PCI would be to turn a complemen-
tary basic surface into a repulsive, negatively charged Biological Implications
surface and prevent the formation of a productive Mi-
chaelis complex. Residues on the surface of tissue kalli- The multiple physiological roles of PCI are still not fully
understood. It is clear from this structure of RCL cleavedkrein that contribute to the negative charge of the inter-
face are D61, E64, E75, E145, D148a, D148, E150, D153, PCI that it has preserved the classical serpin inhibitory
mechanism but that it has also evolved a novel mecha-and E154. Mutation of these residues to lysine or argi-
nine could result in a tissue kallikrein variant whose nism of regulation involving a heparin binding site that
is coincident with the serpin-protease interface. GAGinhibition by PCI is heparin dependent.
The structure of cleaved PCI presented here repre- binding can localize PCI to membrane surfaces, where
its rates of inhibition and specificity are altered. Thus,sents the only structure of a hormone binding serpin.
Its surprising structural feature of an N-terminally short- free PCI in blood or seminal plasma will have targets
that are different from those of the cell surface-boundened helix A provides a highly complementary binding
site for hydrophobic hormones. It would not have been form. The biological relevance of hydrophobic hormone
binding by PCI is unclear. Retinoic acid binding haspossible to predict the extent or position of the helix
A gap in the absence of structural data. The helix A been associated with an increase in molecular weight
of PCI, which may be due to serpin polymerization [22].truncation has independently evolved in the minimal,
viral serpin CrmA, but, as the D helix is missing, no gap Similarly high-molecular weight forms of PCI have been
found intracellularly, where it may then be translocatedexists. Is it possible that the more closely related human
hormone binding serpins have adopted the same strat- to the nucleus to affect gene expression (M.J. Prendes-
Garcia et al., 2001, J. Thromb. and Haemost. Suppl.,egy of helix A shortening to create the hormone binding
helix A gap? Sequence analysis (FASTA 3.2) of the N-ter- July, abstract). It is clear that the serpin architecture is
highly adaptable and can serve many functions in biol-minal peptide of PCI preceding and including helix A
(24SSRRDFTFDLYRALASAAPXQNIFFSPV51) resulted ogy; the structure of cleaved PCI presented here helps
illustrate how.in many hits within the serpin family, but all of the best
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Figure 5. A Proposal for the Heparin Activa-
tion Mechanism of PCI Inhibition of APC
Heparin activation of APC (cyan) inhibition by
PCI (gray;  sheet A, red; RCL, yellow; P1
Arg, orange ball and stick) depends on both
molecules binding to heparin (ball and stick,
yellow bonds)
(A) Since neither molecule binds with a high
degree of specificity for a particular sequence
in heparin, they are free to translate along
heparin, as indicated by the arrows.
(B) Once PCI encounters APC, the electro-
static repulsion of their basic heparin binding
sites is relieved through their cooccupation
of the same site on the heparin chain. Thus,
in the Michaelis complex, APC and PCI sand-
wich heparin in a manner analogous to the
sandwiching of the acidic tail of HCII in its
Michaelis complex with thrombin.
Experimental Procedures specific for cleaved PCI [54]. Initial crystals were obtained from
several conditions and were generally thin plates, which diffracted
poorly. Diffraction quality crystals grew in drops containing 5 mg/Crystal Structure
PCI was purified from fresh human plasma as previously described ml protein, 17% PEG 3350, 3% isopropanol, and 170 mM NaF.
Crystals were cryoprotected in 17% PEG 3350, 120 mM NaF, 20%[52] and subsequently cleaved with porcine pancreatic elestase
(Sigma). PCI cleaved at P2	-P3	 (numbering of Schecter and Berger isopropanol, and 10% 2-methyl-2,4-pentanediol and flash-cooled
in vapor nitrogen (100 K). Screening was conducted in house, and[53]) was purified with a monoclonal antibody-conjugated column
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an initial data set was collected. Although the data were of sufficient 2. Rezaie, A.R., Cooper, S.T., Church, F.C., and Esmon, C.T. (1995).
quality and resolution to solve the structure by molecular replace- Protein C inhibitor is a potent inhibitor of the thrombin-thrombomo-
ment with cleaved 1-antitrypsin as the search model, the combina- dulin complex. J. Biol. Chem. 270, 25336–25339.
tion of high mosaicity and a long cell edge (250 A˚) reduced the 3. Espana, F., Berrettini, M., and Griffin, J.H. (1989). Purification and
effective resolution because of overlaps. To overcome this problem characterization of plasma protein C inhibitor. Thromb. Res. 55,
we collected data at the APS in Argonne, IL, on station 19ID, with an 369–384.
SBC2 3000
 3000 CCD detector. The resulting data were processed 4. Geiger, M., Huber, K., Wojta, J., Stingl, L., Espana, F., Griffin, J.H.,
with HKL2000 [55] and were of much higher quality (Table 1), with and Binder, B.R. (1989). Complex formation between urokinase
useful data to 2.4 A˚ and fully complete data to 2.6 A˚. The structure and plasma protein C inhibitor in vitro and in vivo. Blood 74,
of cleaved PCI was solved by molecular replacement (MolRep) [56] 722–728.
with the structure of cleaved 1-antitrypsin (1ezx) as the search 5. Espana, F., Estelles, A., Fernandez, P.J., Gilabert, J., Sanchez-
model. Four molecules were placed in the asymmetric unit. An initial Cuenca, J., and Griffin, J.H. (1993). Evidence for the regulation of
model of cleaved PCI was constructed on the molecular replace- urokinase and tissue type plasminogen activators by the serpin,
ment solution of cleaved 1-antitrypsin with the program protein C inhibitor, in semen and blood plasma. Thromb. Haemost.
SwissModel [57]. The model was subjected to rigid-body refinement 70, 989–994.
and coordinate refinement with simulated annealing with CNS [58, 6. Laurell, M., and Stenflo, J. (1989). Protein C inhibitor from human
59]. Iterative rounds of rebuilding in XtalView [60] and refinement plasma: characterization of native and cleaved inhibitor and dem-
with CNS resulted in an R factor and Rfree of 22.2 and 27.9, respec- onstration of inhibitor complexes with plasma kallikrein. Thromb.
tively (Table 1). Strict NCS was used for initial refinement, and re- Haemost. 62, 885–891.
strained NCS with decreasing weight was employed subsequently. 7. Espana, F., Fink, E., Sanchez-Cuenca, J., Gilabert, J., Estelles, A.,
The final rounds of refinement did not use NCS restraints. Figures and Witzgall, K. (1995). Complexes of tissue kallikrein with protein
were made with XtalView, Molscript [61], Bobscript [62], Raster3D C inhibitor in human semen and urine. Eur. J. Biochem. 234,
[63], and Spock. Coordinates and structure factors have been de- 641–649.
posited in the Protein Data Bank under ID 1LQ8. Chymotrypsin 8. Ecke, S., Geiger, M., Resch, I., Jerabek, I., Sting, L., Maier, M.,
numbering is used when describing protease residues. and Binder, B.R. (1992). Inhibition of tissue kallikrein by protein C
inhibitor. Evidence for identity of protein C inhibitor with the kalli-
Docking Studies krein binding protein. J. Biol. Chem. 267, 7048–7052.
Docking studies for the binding of all-trans retinoic acid by cleaved 9. Ecke, S., Geiger, M., and Binder, B.R. (1992). Glycosaminoglycans
PCI were carried out with the program DockVision [64]. The coordi- regulate the enzyme specificity of protein C inhibitor. Ann. N Y
nates of all-trans retinoic acid were generated with the program Acad. Sci. 667, 84–86.
CORINA [65], which produces a fully hydrogenated ligand. PCI mo- 10. Ecke, S., Geiger, M., and Binder, B.R. (1997). Heparin binding
nomer GH was hydrogenated with the utility Hydoman included with
of protein-C inhibitor—analysis of the effect of heparin on the
DockVision. Because of the eliptical nature of serpins, two initial
interaction of protein-C inhibitor with tissue kallikrein. Eur. J. Bio-
positions were chosen for retinoic acid near the foci. The maximum
chem. 248, 475–480.
floating radius from the foci was set to 30 A˚, giving good coverage
11. Ecke, S., Geiger, M., Resch, I., Jerabek, I., Maier, M., and Binder,
over the entire surface of PCI. There were 10,000 trials, with a sched-
B.R. (1992). Possible identity of kallikrein binding protein with pro-
ule of six steps (initial step, 300 K, 500 trials, maxrot of 16, maxtrans
tein C inhibitor. Agents Actions Suppl. 38, 182–189.of 6A˚; final step, 10 K, 1000 trials, maxrot of 0.5, maxtrans of 0.25 A˚).
12. Huntington, J.A., Read, R.J., and Carrell, R.W. (2000). Structure of aAn energy cutoff of20 resulted in 2290 solutions and 1378 clusters.
serpin-protease complex shows inhibition by deformation. Nature
407, 923–926.Modeling of Native PCI
13. Huntington, J.A., and Carrell, R.W. (1901). The serpins: nature’sA model of native PCI was created from the structure of cleaved PCI
molecular mousetraps. Sci. Prog. 84, 125–136.by superimposing fragments of the PCI structure on the structure of
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